Loxo Oncology
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Loxo Oncology sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).
Loxo Oncology: 14 sponsored US clinical trials, 2 recruiting.
Loxo Oncology sponsors 14 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 7 completed. 6 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Small Lymphocytic Lymphoma, with 5 trials.
Top-decile sponsor footprint
Loxo Oncology ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
14 total, page 1 of 1
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
NCT05176314
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
NCT05136404
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
NCT05089019
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
NCT04782076
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
NCT05134337
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
NCT05134350
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 1 |
| Phase 3 | 6 |
What is open in the Loxo Oncology pipeline
2 recruiting of 14 indexed (14% open); 7 completed (50%).
Phase mix: 6 late (III/IV) vs 8 early (I/II) (balanced across stages).
Top condition: Small Lymphocytic Lymphoma (5 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Loxo Oncology: open-pipeline peers nationwide
Peers matched on 14 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Loxo Oncology sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 14 trials (± recruiting share)
- 3-C Institute for Social Development · 14 trials · 0% recruiting
- Abbott Medical Optics · 14 trials · 0% recruiting
- Abbott RDx Cardiometabolic · 14 trials · 0% recruiting
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 14 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Loxo Oncology page
14 registered trials is a research-attention snapshot, not an endorsement of Loxo Oncology or any single study.
- 2 of Loxo Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Small Lymphocytic Lymphoma is the condition Loxo Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Small Lymphocytic Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Loxo Oncology pipeline card: 14 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.